Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970335 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL29630385 | 0.97 | BACE1 (0.39) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL29630656 | 0.94 | DPP4 (0.35) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL29630607 | 0.93 | MME (0.38) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL31482979 | 0.93 | MME (0.38) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL29590459 | 0.93 | MME (0.38) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL17768459 | 0.92 | DPP4 (0.40) | DPP4DPP8DPP9BACE1HDAC3 | |
| SCHEMBL2780879 | 0.92 | DPP4 (0.40) | DPP4DPP8DPP9BACE1HDAC3 | |
| SCHEMBL30272504 | 0.91 | BACE1 (0.37) | DPP4DPP8DPP9KMT2AALOX15 | |
| SCHEMBL5970125 | 0.91 | KMT2A (0.40) | DPP4DPP8DPP9KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | claimed |
| US-20220289846-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-09-15 | — | — | US | claimed |
| EP-3997126-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-18 | — | — | EP | claimed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516121-B2 | Antibodies to human programmed death receptor PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-01-06 | — | — | US | disclosed |
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | disclosed |
| US-12427179-B2 | Compositions and methods for diagnosis and treatment of neurodegenerative diseases | Epitracker, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | disclosed |
| US-20230390346-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | BIOMEDIT, LLC | 2023-12-07 | — | — | US | disclosed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | disclosed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | disclosed |
| WO-2019055718-A1 | METABOLOMIC REVISION OF MAMMALIAN INFANTS | Evolve Biosystems, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180320217-A1 | METHODS FOR SAMPLING AND MEASURING ORAL LAVAGE PROTEINS | THE PROCTER & GAMBLE COMPANY | 2018-11-08 | — | — | US | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3221463-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081534-A1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20100323975-A1 | THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2228068-A1 | THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY | Otsuka Pharmaceutical Factory, Inc. (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-20060217321-A1 | Compositions to improve tic disorders | TAIYOKAGAKU CO., LTD. (JP) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | DPP4 3107/4885DPP8 1167/4885DPP9 1915/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | DPP4 1877/4885DPP8 2336/4885DPP9 2337/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | DPP4 1877/4885DPP8 2336/4885DPP9 2337/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | DPP4 1877/4885DPP8 2336/4885DPP9 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.